Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease

Molecular Neurobiology

Volumn 53, Issue 5, 2016, Pages 3136-3145

  Gronewold, Janine ^a   Klafki, Hans Wolfgang ^b,c   Baldelli, Enrico ^a   Kaltwasser, Britta ^a   Seidel, Ulla K ^a   Todica, Olga ^a   Volsek, Michaela ^a   Haußmann, Ute ^b   Wiltfang, Jens ^c   Kribben, Andreas ^a   Bruck, Heike ^a   Hermann, Dirk M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alzheimer s disease; Chronic kidney disease; Neurovascular hypothesis; Peripheral sink hypothesis; Plasma amyloid; Vascular risk factor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBRINOGEN; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; POTASSIUM;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; IMMUNOASSAY; INFLAMMATION; KIDNEY DONOR; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; AGED; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DONOR; KIDNEY; PATHOPHYSIOLOGY;

AGED; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TISSUE DONORS;

EID: 84930168297     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9218-y     Document Type: Article

References (23)

1. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28(4):202–208. doi:10.1016/j.tins.2005.02.001
2. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA (2010) Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid beta-peptide elimination from the brain. J Neurochem 115(5):1077–1089. doi:10.1111/j.1471-4159.2010.07002.x
3. Casserly I, Topol EJ (2004) Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet 363(9415):1139–1146. doi:10.1016/s0140-6736(04)15900-x
4. Moorhouse P, Rockwood K (2008) Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 7(3):246–255. doi:10.1016/s1474-4422(08)70040-1
5. Maier FC, Wehrl HF, Schmid AM, Mannheim JG, Wiehr S, Lerdkrai C, Calaminus C, Stahlschmidt A et al (2014) Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat Med 20(12):1485–1492. doi:10.1038/nm.3734
6. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2):178–201. doi:10.1016/j.neuron.2008.01.003
7. Liu YH, Wang YR, Xiang Y, Zhou HD, Giunta B, Manucat-Tan NB, Tan J, Zhou XF et al (2015) Clearance of amyloid-beta in Alzheimer’s disease: shifting the action site from center to periphery. Mol Neurobiol 51(1):1–7. doi:10.1007/s12035-014-8694-9
8. Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I (2012) Evaluation of plasma Abeta as predictor of Alzheimer’s disease in older individuals without dementia: a population-based study. J Alzheimer's Dis: JAD 28(1):231–238. doi:10.3233/jad-2011-111418
9. Liu YH, Xiang Y, Wang YR, Jiao SS, Wang QH, Bu XL, Zhu C, Yao XQ et al (2014) Association between serum amyloid-beta and renal functions: implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol. doi:10.1007/s12035-014-8854-y
10. Seidel UK, Gronewold J, Volsek M, Todica O, Kribben A, Bruck H, Hermann DM (2014) The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney disease. Kidney Int 85(3):693–702. doi:10.1038/ki.2013.366
11. Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, Berr C, Dartigues JF (2011) Chronic kidney disease, cognitive decline, and incident dementia: the 3C study. Neurology 77(23):2043–2051. doi:10.1212/WNL.0b013e31823b4765
12. Miwa K, Tanaka M, Okazaki S, Furukado S, Yagita Y, Sakaguchi M, Mochizuki H, Kitagawa K (2014) Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology 82(12):1051–1057. doi:10.1212/wnl.0000000000000251
13. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Volsek M et al (2012) Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 35(1):31–39. doi:10.1159/000334742
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002) Am J Kidney Dis: Official J National Kidney Foundation 39(2 Suppl 1):S1–266
15. Seidel UK, Gronewold J, Volsek M, Todica O, Kribben A, Bruck H, Hermann DM (2014) Physical, cognitive and emotional factors contributing to quality of life, functional health and participation in community dwelling in chronic kidney disease. PLoS One 9(3), e91176. doi:10.1371/journal.pone.0091176
16. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H et al (2001) Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 276(46):42645–42657. doi:10.1074/jbc.M102790200
17. Lewczuk P, Esselmann H, Bibl M, Paul S, Svitek J, Miertschischk J, Meyrer R, Smirnov A et al (2004) Electrophoretic separation of amyloid beta peptides in plasma. Electrophoresis 25(20):3336–3343. doi:10.1002/elps.200406068
18. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW et al (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 81(3):481–496
19. ElAli A, Hermann DM (2011) ATP-binding cassette transporters and their roles in protecting the brain. Neuroscientist: Rev J Bringing Neurobiol, Neurol Psychiatry 17(4):423–436. doi:10.1177/1073858410391270
20. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord 16(3):187–190
21. Stenvinkel P, Zoccali C, Ikizler TA (2013) Obesity in CKD—what should nephrologists know? J Am Soc Nephrol: JASN 24(11):1727–1736. doi:10.1681/ASN.2013040330
22. Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, Jno-Charles OC, Norris EH, Strickland S (2014) A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J Exp Med 211(6):1049–1062. doi:10.1084/jem.20131751
23. Boada M, Ortiz P, Anaya F, Hernandez I, Munoz J, Nunez L, Olazaran J, Roca I et al (2009) Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 22(6):325–339. doi:10.1358/dnp.2009.22.6.1395256